Changes in cystic fibrosis transmembrane conductance regulator protein expression prior to and during elexacaftor-tezacaftor-ivacaftor therapy
Background: Defects in expression, maturation or function of the epithelial membrane glycoprotein CFTR are causative for the progressive disease cystic fibrosis. Recently, molecular therapeutics that improve CFTR maturation and functional defects have been approved. We aimed to verify whether we cou...
Saved in:
Main Authors: | Frauke Stanke (Author), Sophia T. Pallenberg (Author), Stephanie Tamm (Author), Silke Hedtfeld (Author), Ella M. Eichhorn (Author), Rebecca Minso (Author), Gesine Hansen (Author), Tobias Welte (Author), Annette Sauer-Heilborn (Author), Felix C. Ringshausen (Author), Sibylle Junge (Author), Burkhard Tümmler (Author), Anna-Maria Dittrich (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2023-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Spirometric and anthropometric improvements in response to elexacaftor/tezacaftor/ivacaftor depending on age and lung disease severity
by: Katharina Schütz, et al.
Published: (2023) -
Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor-Ivacaftor
by: Burkhard Tümmler, et al.
Published: (2023) -
An association study on contrasting cystic fibrosis endophenotypes recognizes <it>KRT8 </it>but not <it>KRT18 </it>as a modifier of cystic fibrosis disease severity and CFTR mediated residual chloride secretion
by: Becker Tim, et al.
Published: (2011) -
Differential effects of ELX/TEZ/IVA on organ-specific CFTR function in two patients with the rare CFTR splice mutations c.273+1G>A and c.165-2A>G
by: Sophia T. Pallenberg, et al.
Published: (2023) -
Qualitative and quantitative evaluation of computed tomography changes in adults with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor: a retrospective observational study
by: Sabine Dettmer, et al.
Published: (2023)